About us: Leadership

Emmanuel's distinguished career spans over 25 years, during which he has successfully led and transformed businesses in the global biotechnology sector. Prior to taking the lead at Igyxos, Emmanuel served as the CEO of Zealand Pharma, CCO of Alnylam and Head of Rare Diseases at Shire, where he played a pivotal role in driving innovation and business growth.

​

With a strong track record of strategic vision and execution, Emmanuel is poised to guide Igyxos into its next phase of development and expansion. His leadership skills, combined with his deep understanding of biotechnology, make him the ideal choice to lead Igyxos through the evolving challenges and opportunities of the industry.

As a highly respected Medical Consultant and expert in fertility, Amir has dedicated his career to advancing clinical and pharmaceutical research in women's health and reproductive medicine. His extensive portfolio of consultancy work and senior positions have equipped him with a strong commercial acumen and a proven track record of building, integrating, motivating, and mentoring medical teams across Europe

Marie-Christine Maurel received a Master of Science degree in Biological Sciences and a Ph.D. in Reproductive Physiology from Pierre & Marie Curie University in Paris, France. She also served as a post-doctoral fellow in Immunology at the Institute Pasteur in Paris. She has more than 25 years' experience as scientist at INRA (National Institute of Agronomic Research) in the fertility field and 10 years' biotech experience since 2012. Her research activity focused on the endocrinology of reproduction, especially on the biochemistry and immunogenic properties of pituitary gonadotropic hormones (FSH, LH and CG).

​

In 2009 she was the winner of the french "National competition for the creation of innovative companies" and founded ReproPharm®, a biotech company based at the INRA center of Tours, France. Since 2012 she was CEO and scientific director at ReproPharm.

​

In 2017, she splitted Repropharm's activities and founded two new and independent companies: Repropharm Vet® for the development of therapeutics in animal health and Igyxos® for the development of therapeutics in human health. Currently, she is the Chief Scientific Officer of Igyxos and the Chaiman of the Board of Directors.

​

In 2011, the French Government nominated her for the Chevalier degree by the National Order of the Legion of Honour, which is the highest order of merit in France.

Thierry Ziegler has more than 25 years of experience in biopharmaceutical development. Prior to joining Igyxos, he led cell therapy production activities at Cellectis. Previously, Dr. Ziegler also served as Head of Process Development at Merck-Serono, as well as head of biopharmaceutical development at Sanofi. During his career, he had the opportunity to work on multiple monoclonal antibodies as well as many other types of Biologics modalities ranging from recombinant proteins to CAR-T cells. He joined Igyxos in February 2021 as Chief Operating Officer to oversee subcontracted activities related to the development of IGX12. In this role, Dr. Ziegler oversees IGX12 CMC development from cell line generation to GMP manufacturing. He received his Ph.D. in bioprocess engineering from the Georgia Institute of Technology in the United States.

Didier Coquoz, PhD in clinical pharmacology, is a 30+ years seasoned pharma R&D executive (VP R&D and CEO). He has been instrumental in the development/regulatory management from the development candidate up to phase and including III studies and registration of close to 40 biologics, monoclonal antibodies, peptides, cell-based therapeutics, NCEs, of which 4 reached the market world-wide and one has been recently sold to a European pharma that is running its final phase III program. He is/was instrumental within small, medium and large biotech/pharmas.

​

He held positions as CEO and VP R&D on both sides of the Atlantic. He is currently active at designing and supporting the manufacturing, toxicology, clinical and regulatory programs of selected biotechs.